Precision Medicine in Oncology® | Specialty

Is Breast Cancer Vaccination Coming?

October 1st 2014

Dr. Patrick Borgen Talks About Advances in Breast Cancer

October 1st 2014

Dr. Patrick Borgen Discusses the "Jolie Effect"

October 1st 2014

Dr. Patrick Borgen on the Future of Breast Cancer Treatment

October 1st 2014

The Ongoing Debate Over Mammography-Screening Matters

October 1st 2014

Prophylactic Double Mastectomy-Does it Make a Difference?

October 1st 2014

ATEMPT Trial at Dana-Farber Cancer Institute

October 1st 2014

BRCA Screening Recommendations by Geneticist Mary-Claire King

October 1st 2014

Latest News & Insight: October 1, 2014

October 1st 2014

EGFR Pioneer Keeps Focus on Individualizing Patient Care in Lab and Clinic

October 1st 2014

As director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, Thomas J. Lynch Jr, MD, wears many hats. And, having built a career united around two abiding goals of clinical discovery and personalized patient care, that's just the way he likes it.

Dr. Ledermann Discusses Olaparib in Ovarian Cancer

October 1st 2014

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

Expanded 80405 Study Mutation Analysis Fails to Resolve Targeted Therapy Quandary in mCRC

September 30th 2014

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

Multiple Factors Impact BRCA Testing Decision

September 23rd 2014

More than one-third of patients with breast or ovarian cancer or a family history of those diseases who also saw a genetic counselor did not pursue genetic testing for BRCA 1 or BRCA 2 mutations.

Dr. Lazarus Discusses Companion Diagnostics

September 18th 2014

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

Genetic Cancer Screening for All?: The Evolving BRCA1/BRCA2 Story

September 18th 2014

Numerous epidemiological factors affect the likelihood of developing breast and ovarian cancer, but no other predictor is as powerful as an inherited mutation in BRCA1 or BRCA2, genes involved in both tumor suppression and DNA repair.

Blood-Based Biomarkers Predict Outcomes Following Neoadjuvant Treatment in Esophageal Cancer

September 16th 2014

High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Beyond the Clinical Trial

September 14th 2014

Oncologists Need Guideposts for Recommending Drugs Not Studied in Cancers

Urologists Discuss Their Use of Biomarker Tests in Considering Active Surveillance

September 12th 2014

Experts Touch On Oncotype DX, Other Assays During Peer Exchange

Molecular Era Tumor Boards: Team Approach to Interpreting Genomic Test Results Proves Valuable

September 11th 2014

How can a conscientious but very busy practitioner keep up with the massive quantity of molecular data that could potentially impact an individual patient with cancer? The Moores Cancer Center at the University of California, San Diego has updated the tumor board concept for the molecular era.

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

September 11th 2014

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.